Should treatments offered to older men with high risk prostate cancer be different than for younger men? Researchers from the University of California, San Francisco found that older men were denied more aggressive treatments because of their age. Men older than 75 years of age with high-risk prostate cancer often are under-treated when compared to [...]
A member of the advanced prostate cancer on-line group recently posted about his experience using the newly approved chemotherapy agent, Jevtana (cabazitaxel). His post included not only a report about his PSA response to the drug, but his experiences with side effects and a suggested method of controlling one of the debilitating side effect, diarrhea. [...]
The latest from Jan Manarite of PCRI about the getting early access to Abiraterone for men with advanced prostate cancer and who have failed chemotherapy: Abiraterone expanded Access Trial Site Contact Info – 2/7/11 (800) 457-6399 M-F, 9am –5pm, EST TRIAL link: http://www.clinicaltrials.gov/ct2/show/NCT01217697?term=abiraterone&recr=Open&rank=6 Basic Criteria: 1. testosterone less than 50 2. metastatic 3. no brain [...]
A recent study conducted at the Southeast Louisiana Veterans Health Care System, New Orleans, LA, USA by the Section of Hematology and Medical Oncology, Tulane University School of Medicine, New Orleans, LA, evaluated the efficacy of the timely use of zoledronic acid (ZA) on clinical outcomes and health care utilization in men with bone-metastatic prostate [...]
There are two different dosage levels used for the administration of Ketoconazole (Keto), a commonly used 2nd line hormone deprivation drug used after the failure of the traditional drugs (Lupron, Zoladex etc.). Low dosage keto involves taking 200 mg three times a day (600 mg per day), while high dose keto uses 400 three times [...]